Skip to main content

Garay Arpa's Form 4 filing

Moderna, Inc. (MRNA) · filed Sep 7, 2023

Accession no.
0001127602-23-023856
Filed
Sep 7, 2023
Trade date
Sep 5-6, 2023
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $62.2K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Garay ArpaCIK 0001916360Officer (Chief Commercial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 5, 2023Common StockMOption exerciseAcquired+1,140–F1–3,687Direct
Sep 6, 2023Common StockSSaleDisposed−574$108.40−$62,221.63,113Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 5, 2023Common StockMOption exerciseDisposed−1,140$0.00$012,546Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Restricted stock units convert into common stock on a one-for-one basis.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)